Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients with gastroenteropancreatic neuroendocrine tumors, a phase 3 trial found.
Effect of marital status and race on survival of patients with well differentiated neuroendocrine tumors (NETs). Clinicopathological factors related to survival in gastroenteropancreatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback